Merz Pharmaceuticals, Eckenheimer Landstrasse 100, D-60318, Frankfurt, Germany.
Neuropharmacology. 2019 Mar 15;147:4-10. doi: 10.1016/j.neuropharm.2018.08.027. Epub 2018 Aug 27.
Drug repurposing is recently gaining increasing attention, not just from pharmaceutical companies but also from government agencies in an attempt to generate new medications to address increasing unmet medical needs in a cost effective and expedite manner. There are several approaches to identify novel indications for known drugs. Many are based on rational selection e.g. the known or a new mechanism of action of a drug. This review will focus rather on phenotypic or high content screening of compounds in models that are believed to be predictive of effectiveness of compounds irrespective of their mechanism of action. Three short cases studies of screens for Alzheimer's disease, Parkinson's disease and spasticity will be given as examples. This article is part of the Special Issue entitled 'Drug Repurposing: old molecules, new ways to fast track drug discovery and development for CNS disorders'.
药物重定位最近受到越来越多的关注,不仅受到制药公司的关注,也受到政府机构的关注,试图以经济有效的方式产生新的药物来满足不断增长的未满足的医疗需求。有几种方法可以确定已知药物的新适应症。许多方法都是基于合理选择的,例如药物的已知或新作用机制。本综述将主要关注在模型中对化合物进行表型或高通量筛选,这些模型被认为可以预测化合物的有效性,而不论其作用机制如何。将给出三个针对阿尔茨海默病、帕金森病和痉挛性疾病的筛选的简短案例研究作为示例。本文是专题“药物重定位:旧分子,新方法,加速 CNS 疾病药物发现和开发”的一部分。